Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaN. Engl. J. Med 2021 Feb 13;[EPub Ahead of Print], R Motzer, B Alekseev, S-Y Rha, et al
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.